Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONES 3: Solriamfetol for Excessive Sleepiness in OSA
NCT02348606Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2015
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of solriamfetol in obstructive sleep apnea (OSA) (5 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Maintenance of Wakefulness Test at 12 weeks and Epworth Sleepiness Scale at 12 weeks. Started May 2015; status: completed.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT02348606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348606.